XML 47 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Quarterly Results of Operations (unaudited)
 12 Months Ended
Dec. 31, 2024
Quarterly Financial Data [Abstract]  
Quarterly Results of Operations (unaudited) Quarterly Results of Operations (unaudited)
The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:

For the Three Months Ended
December 31September 30June 30March 31
2024
Total revenue$646,542 $621,401 $647,145 $639,653 
Total operating expenses665,138637,669639,357653,062
Gain (loss) before preferred dividends and accretion of Series A Preferred Stock(22,802)(23,137)1,596(17,280)
Dividends and accretion of Series A Preferred Stock(7,813)(8,094)(7,979)(7,945)
Net loss attributable to common shareholders of Evolent Health, Inc.(30,615)(31,231)(6,383)(25,225)
Loss per common share
Basic and diluted$(0.27)$(0.27)$(0.06)$(0.22)
2023
Total revenue$556,055 $511,015 $469,136 $427,690 
Total operating expenses577,405528,953490,704438,045
Loss before preferred dividends and accretion of Series A Preferred Stock(33,411)(25,324)(34,323)(19,982)
Dividends and accretion of Series A Preferred Stock(7,984)(7,872)(7,088)(6,276)
Net loss attributable to common shareholders of Evolent Health, Inc.(41,395)(33,196)(41,411)(26,258)
Loss per common share
Basic and diluted$(0.36)$(0.30)$(0.37)$(0.24)